Abstract | BACKGROUND: METHODS: The prospective, randomized, 2-center trial was designed to compare the effect of 3 different vasodilators on coronary no-reflow. A total of 102 patients with no-reflow in primary PCI were randomized to receive intracoronary infusion of diltiazem, verapamil, or nitroglycerin (n = 34 in each group) through selective microcatheter. The primary end point was coronary flow improvement in corrected thrombolysis in myocardial infarction frame count ( CTFC) after administration of the drug. RESULTS: CONCLUSION:
|
Authors | Dong Huang, Juying Qian, Lei Ge, Xuejuan Jin, Huigen Jin, Jianying Ma, Zongjun Liu, Feng Zhang, Lili Dong, Xiangfei Wang, Kang Yao, Junbo Ge |
Journal | American heart journal
(Am Heart J)
Vol. 164
Issue 3
Pg. 394-401
(Sep 2012)
ISSN: 1097-6744 [Electronic] United States |
PMID | 22980307
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright © 2012 Mosby, Inc. All rights reserved. |
Chemical References |
- Troponin T
- Vasodilator Agents
- Natriuretic Peptide, Brain
- Verapamil
- Diltiazem
- Nitroglycerin
|
Topics |
- Aged
- Coronary Circulation
(drug effects, physiology)
- Diltiazem
(administration & dosage, adverse effects)
- Electrocardiography
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(drug therapy, physiopathology)
- Natriuretic Peptide, Brain
(blood, drug effects)
- Nitroglycerin
(administration & dosage, adverse effects)
- Percutaneous Coronary Intervention
- Prospective Studies
- Treatment Outcome
- Troponin T
(blood, drug effects)
- Vasodilator Agents
(administration & dosage, adverse effects)
- Verapamil
(administration & dosage, adverse effects)
|